Anebulo Pharmaceuticals, Inc. (ANEB) — SEC Filings
Anebulo Pharmaceuticals, Inc. (ANEB) — 21 SEC filings. Latest: 8-K (Dec 22, 2025). Includes 12 8-K, 6 10-Q, 2 10-K.
View Anebulo Pharmaceuticals, Inc. on SEC EDGAR
Overview
Anebulo Pharmaceuticals, Inc. (ANEB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: Anebulo Pharmaceuticals, Inc. filed an 8-K on December 22, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant filing sentiment for Anebulo Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Anebulo Pharmaceuticals, Inc. (ANEB) has filed 12 8-K, 6 10-Q, 2 10-K, 1 DEF 14A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of ANEB's 20 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$2.16M |
| EPS | -$0.05 |
| Debt-to-Equity | N/A |
| Cash Position | $10.35M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Industry Context
Anebulo Pharmaceuticals operates in the biopharmaceutical sector, specifically focusing on developing treatments for substance-induced toxicities, with a primary candidate for cannabis-induced toxicity. This is a niche but potentially growing area within the broader addiction and neurological disorder treatment market. The industry is characterized by high R&D costs, long development cycles, stringent regulatory oversight, and significant competition from both large pharmaceutical companies and smaller biotech firms.
Top Tags
10-Q (5) · pharmaceuticals (5) · regulatory-filing (4) · 8-K (3) · financials (3) · sec-filing (3) · Biotechnology (2) · Clinical Stage (2) · filing (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $2.16M | Decreased from $2.20M in Q1 2024, showing a slight improvement in profitability. |
| Cash and Cash Equivalents | $10.35M | Decreased from $11.63M at June 30, 2025, indicating ongoing cash burn. |
| Accumulated Deficit | $76.05M | Increased from $73.89M at June 30, 2025, reflecting continued operating losses. |
| Research and Development Expenses | $809,991 | Decreased by 38.5% from $1,314,859 in Q1 2024, impacting future product pipeline. |
| General and Administrative Expenses | $1,450,269 | Increased by 32.2% from $1,097,265 in Q1 2024, contributing to operating costs. |
| Common Shares Outstanding | 41,084,731 | As of September 30, 2025, indicating potential for future dilution. |
| Net Loss Per Share | $0.05 | Improved from $0.08 in Q1 2024, despite increased share count. |
| Net Proceeds from Securities Purchase Agreement | $14.9M | Received in December 2024, providing critical liquidity for operations. |
| Liquidity Horizon | 12 months | Expected duration of current cash and funding, necessitating future financing. |
| R&D Expense Decrease | 38.5% | Significant reduction in research and development spending year-over-year. |
| Aggregate market value of non-affiliate common stock | $15,057,677 | As of December 31, 2024, indicating a small market capitalization for a public company. |
| Shares of common stock outstanding | 41,084,731 | As of September 25, 2025, relevant for per-share calculations and potential dilution. |
| Cannabis-related emergency department patient visits | 1.1 million | Estimated in 2014, highlighting the significant market need for selonabant. |
| Revenue since inception | $0 | Indicates the company is in a pre-commercial stage and relies on financing. |
| Reporting Period | Q3 2025 | The 10-Q covers the third quarter of fiscal year 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Anebulo Pharmaceuticals, Inc. (ANEB)?
Anebulo Pharmaceuticals, Inc. has 21 recent SEC filings from Feb 2024 to Dec 2025, including 12 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANEB filings?
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Anebulo Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anebulo Pharmaceuticals, Inc. (ANEB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anebulo Pharmaceuticals, Inc.?
Key financial highlights from Anebulo Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANEB?
The investment thesis for ANEB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Anebulo Pharmaceuticals, Inc.?
Executive information for Anebulo Pharmaceuticals, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Anebulo Pharmaceuticals, Inc. stock?
Of ANEB's 20 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Anebulo Pharmaceuticals, Inc.?
Forward guidance and predictions for Anebulo Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.